Novo Nordisk's Ziltivekimab Fails Phase III ZEUS Trial, Shaking Cardiometabolic and Anti-Inflammatory Pipelines
On July 31, 2026, Novo Nordisk A/S (NYSE: NVO) announced that its late-stage anti-inflammatory cardiovascular drug ziltivekimab failed to meet its primary endpoint in the Phase III ZEUS clinical trial. This high-profile clinical failure represents a major setback for Novo Nordisk's strategy to expand beyond metabolic care into the adjacent, high-volume cardiovascular and chronic kidney disease markets.
During Novo Nordisk's Q2 2026 earnings call on August 5, 2026, management provided critical details regarding the trial's outcomes and the drug's future development path.
The ZEUS Trial Results: Target Engagement Without Clinical Benefit
Ziltivekimab, a fully human monoclonal antibody designed to inhibit interleukin-6 (IL-6), was evaluated in the ZEUS trial to determine if reducing systemic inflammation could lower the risk of major adverse cardiovascular events (MACE) in patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and systemic inflammation.
While the trial successfully demonstrated ziltivekimab's biological activity, this did not translate into clinical efficacy:
- No MACE Reduction: Ziltivekimab achieved target engagement, successfully inhibiting the IL-6 pathway as reflected by a significant reduction in high-sensitivity C-reactive protein (hsCRP) and free IL-6. However, this biological response failed to reduce the incidence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke, yielding a disappointing hazard ratio of 0.99 (placebo-adjusted).
- Adverse Safety Signal: Consistent with the systemic immunosuppressive effects of IL-6 inhibition, a higher proportion of patients treated with ziltivekimab experienced serious infections compared to those on placebo.
Novo Nordisk's Executive Vice President and Head of Development, Martin Holst Lange, addressed the clinical disconnect during the earnings call:
"While ziltivekimab showed target engagement and inhibition of the IL-6 pathway as reflected by expected reduction in free IL-6 and hsCRP respectively, this does not translate into MACE reductions with a hazard ratio of 0.99. Consistent with targeting IL-6 inhibition, a higher proportion of people treated with ziltivekimab had serious infections compared to placebo."
Competitive and Strategic Impact
The failure of ziltivekimab in the ZEUS trial is a significant blow to Novo Nordisk's diversification strategy. The company has been eager to establish clinical benefits in cardiovascular outcomes to combat pricing pressures and defend its premium pricing in the U.S. market.
While Novo Nordisk has successfully demonstrated cardiovascular benefits with its semaglutide portfolio (e.g., the SELECT trial for Wegovy and the newly FDA-approved cardiovascular indication for oral Ozempic in May 2026), ziltivekimab was expected to be a cornerstone of its non-incretin cardiovascular pipeline.
Despite the setback, Novo Nordisk has not completely abandoned the asset. Management confirmed that they are continuing to evaluate ziltivekimab in two other ongoing Phase III trials (the SUS programs) to see if a clinical benefit can be established in other specific patient populations where inflammation plays a different pathological role.